VCYT Q2 2025 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$130M+13.8% YoY

Gross Profit

$90M69.0% margin

Operating Income

-$5M-4.0% margin

Net Income

-$980,000-0.8% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$32M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$123M

Stockholders' Equity

$1.2B

Cash & Equivalents

$219M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$114M	+13.8%
Gross Profit	$90M	$78M	+15.2%
Operating Income	-$5M	$5M	-214.4%
Net Income	-$980,000	$6M	-117.1%

Revenue Segments

Testing

$122M94%

Biopharmaceutical And Other

$4M3%

Product

$4M3%